These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

159 related items for PubMed ID: 1578768

  • 21. The use of desferrioximine in dialysis-associated aluminium disease.
    Ackrill P, Day JP.
    Contrib Nephrol; 1993; 102():125-34. PubMed ID: 8416177
    [No Abstract] [Full Text] [Related]

  • 22. Desferrioxamine in the treatment of aluminum overload.
    Ackrill P, Day JP.
    Clin Nephrol; 1985; 24 Suppl 1():S94-7. PubMed ID: 3842106
    [Abstract] [Full Text] [Related]

  • 23. Clinical and histologic features of iron-related bone disease in dialysis patients.
    McCarthy JT, Hodgson SF, Fairbanks VF, Moyer TP.
    Am J Kidney Dis; 1991 May; 17(5):551-61. PubMed ID: 2024657
    [Abstract] [Full Text] [Related]

  • 24. Aluminum-associated bone disease: considerations on the pathogenesis and the effects of deferoxamine treatment.
    Kurokawa K, Marumo F, Ogura Y, Ono T, Suzuki M.
    J UOEH; 1987 Mar 20; 9 Suppl():133-9. PubMed ID: 3602744
    [No Abstract] [Full Text] [Related]

  • 25. Clinical practice guidelines for bone metabolism and disease in chronic kidney disease: an overview.
    Bailie GR, Massry SG, National Kidney Foundation.
    Pharmacotherapy; 2005 Dec 20; 25(12):1687-707. PubMed ID: 16305288
    [Abstract] [Full Text] [Related]

  • 26. [Methods of correcting hyperphosphatemia in chronic renal failure and in dialysis (review)].
    Novikov AI.
    Ter Arkh; 1997 Dec 20; 69(12):63-7. PubMed ID: 9503540
    [No Abstract] [Full Text] [Related]

  • 27. Aluminum-related osteomalacia in renal-failure patients.
    Vick KE, Johnson CA.
    Clin Pharm; 1985 Dec 20; 4(4):434-9. PubMed ID: 3899471
    [Abstract] [Full Text] [Related]

  • 28. Encephalopathy in chronic renal failure responsive to deferoxamine therapy. Another manifestation of aluminum neurotoxicity.
    Sprague SM, Corwin HL, Wilson RS, Mayor GH, Tanner CM.
    Arch Intern Med; 1986 Oct 20; 146(10):2063-4. PubMed ID: 3767553
    [Abstract] [Full Text] [Related]

  • 29. [Complications suffered by dialysis patients. 5. Dialysis-induced amyloidosis].
    Gejo F, Takahashi N.
    Nihon Naika Gakkai Zasshi; 2000 Jul 10; 89(7):1372-8. PubMed ID: 11032505
    [No Abstract] [Full Text] [Related]

  • 30. Deferoxamine (DFO): the effectiveness for noninvasive diagnosis of aluminum-related bone disease, and for treatment of the disease.
    Marumo F, Umetani N, Sato N, Takahashi Y.
    J UOEH; 1987 Mar 20; 9 Suppl():140-52. PubMed ID: 3602745
    [No Abstract] [Full Text] [Related]

  • 31. Diagnosis and treatment of aluminium overload in end-stage renal failure patients.
    Nephrol Dial Transplant; 1993 Mar 20; 8 Suppl 1():1-4. PubMed ID: 8389013
    [No Abstract] [Full Text] [Related]

  • 32. Aluminum-related osteodystrophy.
    Sherrard DJ, Andress DL.
    Adv Intern Med; 1989 Mar 20; 34():307-23. PubMed ID: 2644762
    [Abstract] [Full Text] [Related]

  • 33. Arthropathies associated with renal disease including dialysis-related amyloid.
    Ford PM.
    Curr Opin Rheumatol; 1992 Feb 20; 4(1):63-7. PubMed ID: 1543664
    [Abstract] [Full Text] [Related]

  • 34. Detoxification in hemosiderosis.
    Simon P.
    Blood Purif; 1985 Feb 20; 3(1-3):75-88. PubMed ID: 3913449
    [Abstract] [Full Text] [Related]

  • 35. [Severe ocular toxicity of desferrioxamine in the hemodialyzed patient].
    Bournerias F, Monnier N, Dufier JL, Réveillaud RJ.
    Nephrologie; 1987 Feb 20; 8(1):27-9. PubMed ID: 3587485
    [Abstract] [Full Text] [Related]

  • 36. Exacerbation of aluminium encephalopathy after treatment with desferrioxamine.
    Lillevang ST, Pedersen FB.
    Nephrol Dial Transplant; 1989 Feb 20; 4(7):676. PubMed ID: 2510071
    [No Abstract] [Full Text] [Related]

  • 37. Aluminum and iron overload in chronic dialysis.
    Ackrill P, Day JP, Ahmed R.
    Kidney Int Suppl; 1988 Mar 20; 24():S163-7. PubMed ID: 3283407
    [No Abstract] [Full Text] [Related]

  • 38. Clinical practice guideline for the management of chronic kidney disease-mineral and bone disorder.
    Fukagawa M, Yokoyama K, Koiwa F, Taniguchi M, Shoji T, Kazama JJ, Komaba H, Ando R, Kakuta T, Fujii H, Nakayama M, Shibagaki Y, Fukumoto S, Fujii N, Hattori M, Ashida A, Iseki K, Shigematsu T, Tsukamoto Y, Tsubakihara Y, Tomo T, Hirakata H, Akizawa T, CKD-MBD Guideline Working Group, Japanese Society for Dialysis Therapy.
    Ther Apher Dial; 2013 Jun 20; 17(3):247-88. PubMed ID: 23735142
    [No Abstract] [Full Text] [Related]

  • 39. Aluminum intoxication of bone in renal failure--fact or fiction?
    Malluche HH, Faugere MC, Smith AJ, Friedler RM.
    Kidney Int Suppl; 1986 Feb 20; 18():S70-3. PubMed ID: 3458000
    [No Abstract] [Full Text] [Related]

  • 40. Calcium carbonate in hyperphosphatemia.
    Mayo M, Middleton RK.
    DICP; 1991 Sep 20; 25(9):945-7. PubMed ID: 1949973
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.